COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
Sahar Memar Montazerin (talk | contribs)
Line 18: Line 18:
*[[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
*[[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
*[[User:Mounika|Mounika Vadiyala, M.B.B.S.]]
*[[User:Mounika|Mounika Vadiyala, M.B.B.S.]]
*[[User:SHaddadi|Sara Haddadi, M.D.]]
*[[User:Sara Haddadi|Sara Haddadi, M.D.]]
*[[User:Sara Zand|Sara Zand, M.D.]]
*[[User:Sara Zand|Sara Zand, M.D.]]
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]]
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]]

Revision as of 00:14, 21 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members

Pediatrics and COVID-19

Pulmonary Disorders and COVID-19 Team Members